
Auris Medical Holding Ltd. Long-Term Debt 2011-2026 | EARS
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Auris Medical Holding Ltd.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 5.58 M | 10.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 5.58 M | 7.87 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
AbCellera Biologics
ABCL
|
137 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
ADMA Biologics
ADMA
|
69.3 M | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
130 K | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | ||
|
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
Anika Therapeutics
ANIK
|
26.9 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
ANI Pharmaceuticals
ANIP
|
309 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Apellis Pharmaceuticals
APLS
|
93.3 M | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | ||
|
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | ||
|
Athersys
ATHX
|
8.76 M | - | 3.77 % | $ 22.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
47.9 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
AVEO Pharmaceuticals
AVEO
|
12.7 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
118 M | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
2.01 B | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
171 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B | ||
|
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
25.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
22.7 M | - | -7.31 % | $ 87 M | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
BioLineRx Ltd.
BLRX
|
2.74 M | $ 2.72 | -3.31 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
436 K | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
CymaBay Therapeutics
CBAY
|
467 K | - | - | $ 3.45 B | ||
|
Codexis
CDXS
|
28.9 M | $ 1.25 | 16.2 % | $ 91.8 M | ||
|
Cabaletta Bio
CABA
|
1.46 M | $ 3.2 | -6.71 % | $ 3.74 M | ||
|
Coherus BioSciences
CHRS
|
351 K | $ 1.76 | -0.28 % | $ 166 M | ||
|
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
437 M | - | -7.23 % | $ 13 M |